Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24784205 | 0.87 | KMT2A (0.49) | GLAALDH1A1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL2811457 | 0.84 | GLA (0.44) | GLAALDH1A1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL7004839 | 0.84 | SIGMAR1 (0.52) | SIGMAR1 | |
| SCHEMBL26579714 | 0.82 | GLA (0.52) | GLAALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL259485 | 0.82 | GLA (0.47) | GLAALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL25118852 | 0.82 | SIGMAR1 (0.41) | OPRM1SIGMAR1 | |
| SCHEMBL22282225 | 0.82 | TSHR (0.47) | GLAALDH1A1POLBLMNAMEN1 | |
| SCHEMBL29889549 | 0.81 | SMN1; SMN2 (0.44) | GLAALDH1A1SMN1; SMN2POLBLMNA | |
| SCHEMBL3673101 | 0.81 | GLA (0.46) | GLAALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL7004890 | 0.80 | HRH3 (0.46) | GLAALDH1A1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109580756-A | Composition applied to Capillary Electrophoresis | 杨翠芳 | 2019-04-05 | — | — | CN | claimed |
| US-RE47493-E1 | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-07-09 | — | — | US | disclosed |
| EP-2964617-B1 | SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | BOEHRINGER INGELHEIM INT (DE) | 2017-04-12 | — | — | EP | disclosed |
| US-9115093-B2 | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-08-25 | — | — | US | disclosed |
| US-9115093-B2 | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-08-25 | — | — | US | disclosed |
| US-20140249129-A1 | Substituted Bicyclic Dihydropyrimidinones And Their Use As Inhibitors Of Neutrophil Elastase Activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-04 | — | — | US | disclosed |
| US-20140249129-A1 | Substituted Bicyclic Dihydropyrimidinones And Their Use As Inhibitors Of Neutrophil Elastase Activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-04 | — | — | US | disclosed |
| US-8183234-B2 | Tricyclic guanidine derivatives as sodium-proton exchange inhibitors | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-05-22 | — | — | US | disclosed |
| US-8183234-B2 | Tricyclic guanidine derivatives as sodium-proton exchange inhibitors | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-05-22 | — | — | US | disclosed |
| EP-1594870-B1 | SUBSTITUTED INDOLEPYRIDINIUM AS ANTI-INFECTIVE COMPOUNDS | TIBOTEC PHARM LTD (IE) | 2011-05-11 | — | — | EP | disclosed |
| US-20100267690-A1 | TRICYCLIC GUANIDINE DERIVATIVES AS SODIUM-PROTON EXCHANGE INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-10-21 | — | — | US | disclosed |
| US-20100267690-A1 | TRICYCLIC GUANIDINE DERIVATIVES AS SODIUM-PROTON EXCHANGE INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-10-21 | — | — | US | disclosed |
| US-20100048563-A1 | SUBSTITUTED INDOLEPYRIDINIUM AS ANTI-INFECTIVE COMPOUNDS | KESTELEYN BART RUDOLF ROMANIE | 2010-02-25 | — | — | US | disclosed |
| US-20100048563-A1 | SUBSTITUTED INDOLEPYRIDINIUM AS ANTI-INFECTIVE COMPOUNDS | KESTELEYN BART RUDOLF ROMANIE | 2010-02-25 | — | — | US | disclosed |
| US-7608726-B2 | 5-(2-Morpholin-4-yl-ethyl)-1-(4-nitro-phenyl)-2-oxo-2,5-dihydro-1H-pyrido[3,2-b]indole-3-carbonitrile; 5-isobutyl-1-(4-nitro-phenyl)-2-oxo-2,5-dihydro-1H-pyrido[3,2-b]indole-3-carbonitrile; anti-retroviral agent | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2009-10-27 | — | — | US | disclosed |
| US-7608726-B2 | 5-(2-Morpholin-4-yl-ethyl)-1-(4-nitro-phenyl)-2-oxo-2,5-dihydro-1H-pyrido[3,2-b]indole-3-carbonitrile; 5-isobutyl-1-(4-nitro-phenyl)-2-oxo-2,5-dihydro-1H-pyrido[3,2-b]indole-3-carbonitrile; anti-retroviral agent | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2009-10-27 | — | — | US | disclosed |
| US-20070299051-A1 | Tricyclic Guanidine Derivatives as Sodium-Proton Exchange Inhibitors | NICHOLAS PIRAMAL INDIA LIMITED. (IN) | 2007-12-27 | — | — | US | disclosed |
| US-20070299051-A1 | Tricyclic Guanidine Derivatives as Sodium-Proton Exchange Inhibitors | NICHOLAS PIRAMAL INDIA LIMITED. (IN) | 2007-12-27 | — | — | US | disclosed |
| US-20070249655-A1 | 4-Substituted-1,5-Dihydro-Pyrido[3,2-B]Indol-2-Ones | KESTELEYN BART R R | 2007-10-25 | — | — | US | disclosed |
| US-20070249655-A1 | 4-Substituted-1,5-Dihydro-Pyrido[3,2-B]Indol-2-Ones | KESTELEYN BART R R | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249129-A1 | Substituted Bicyclic Dihydropyrimidinones And Their Use As Inhibitors Of Neutrophil Elastase Activity | SERPINB1, ELANE, MPO | GLA 323/4885ALDH1A1 109/4885SMN1; SMN2 2865/4885 |
| US-20070249655-A1 | 4-Substituted-1,5-Dihydro-Pyrido[3,2-B]Indol-2-Ones | CYP8B1, CYP2S1, CYC1 | GLA 4490/4885ALDH1A1 954/4885SMN1; SMN2 3333/4885 |
| US-20100267690-A1 | TRICYCLIC GUANIDINE DERIVATIVES AS SODIUM-PROTON EXCHANGE INHIBITORS | ATP2A1, ATP2A3, KCNN4 | GLA 1452/4885ALDH1A1 1222/4885SMN1; SMN2 3205/4885 |
| US-20070299051-A1 | Tricyclic Guanidine Derivatives as Sodium-Proton Exchange Inhibitors | ATP2A1, ATP2A3, KCNN4 | GLA 1452/4885ALDH1A1 1222/4885SMN1; SMN2 3205/4885 |
| US-20100048563-A1 | SUBSTITUTED INDOLEPYRIDINIUM AS ANTI-INFECTIVE COMPOUNDS | LTC4S, CYP8B1, CYP2E1 | GLA 4536/4885ALDH1A1 995/4885SMN1; SMN2 4500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.